Heron Therapeutics IncNASDAQ:HRTX
- LAST PRICE1.1900
- TODAY'S CHANGE (%)0.0300 (2.5862%)
- Bid / Lots1.1500/ 1
- Ask / Lots1.2100/ 2
- Open / Previous Close1.1800 / 1.1600
- Day Range
- 52 Week Range
- Volume783,283
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HRTX |
|---|---|---|
| 09:32 ET | 57626 | 1.2 |
| 09:33 ET | 23177 | 1.205 |
| 09:35 ET | 6262 | 1.205 |
| 09:37 ET | 600 | 1.205 |
| 09:39 ET | 5658 | 1.19 |
| 09:42 ET | 7058 | 1.185 |
| 09:44 ET | 700 | 1.19 |
| 09:46 ET | 989 | 1.19 |
| 09:48 ET | 17643 | 1.205 |
| 09:50 ET | 4524 | 1.2 |
| 09:51 ET | 1000 | 1.2 |
| 09:53 ET | 900 | 1.205 |
| 09:55 ET | 550 | 1.2089 |
| 09:57 ET | 150 | 1.205 |
| 10:00 ET | 1341 | 1.2089 |
| 10:02 ET | 1400 | 1.205 |
| 10:04 ET | 6497 | 1.22 |
| 10:06 ET | 30265 | 1.205 |
| 10:08 ET | 500 | 1.205 |
| 10:09 ET | 300 | 1.205 |
| 10:11 ET | 500 | 1.205 |
| 10:13 ET | 2300 | 1.2098 |
| 10:15 ET | 3251 | 1.205 |
| 10:18 ET | 2700 | 1.205 |
| 10:20 ET | 14900 | 1.2 |
| 10:22 ET | 50300 | 1.195 |
| 10:24 ET | 100 | 1.195 |
| 10:26 ET | 101 | 1.19 |
| 10:27 ET | 972 | 1.195 |
| 10:29 ET | 5220 | 1.185 |
| 10:31 ET | 14000 | 1.175 |
| 10:33 ET | 3739 | 1.18 |
| 10:36 ET | 9243 | 1.17 |
| 10:38 ET | 13160 | 1.175 |
| 10:40 ET | 200 | 1.175 |
| 10:42 ET | 2411 | 1.175 |
| 10:44 ET | 19979 | 1.175 |
| 10:45 ET | 185 | 1.1789 |
| 10:49 ET | 3500 | 1.175 |
| 10:51 ET | 8900 | 1.18 |
| 10:54 ET | 200 | 1.185 |
| 10:56 ET | 9937 | 1.19 |
| 10:58 ET | 19095 | 1.2 |
| 11:00 ET | 4029 | 1.2 |
| 11:02 ET | 5298 | 1.1999 |
| 11:05 ET | 497 | 1.195 |
| 11:09 ET | 1217 | 1.195 |
| 11:12 ET | 3200 | 1.195 |
| 11:14 ET | 2400 | 1.195 |
| 11:16 ET | 21481 | 1.195 |
| 11:18 ET | 21200 | 1.195 |
| 11:20 ET | 2500 | 1.2 |
| 11:21 ET | 17996 | 1.191 |
| 11:23 ET | 8963 | 1.21 |
| 11:25 ET | 300 | 1.205 |
| 11:30 ET | 2191 | 1.21 |
| 11:32 ET | 3000 | 1.201 |
| 11:34 ET | 2700 | 1.2099 |
| 11:36 ET | 1000 | 1.2043 |
| 11:38 ET | 100 | 1.21 |
| 11:39 ET | 900 | 1.205 |
| 11:41 ET | 4010 | 1.205 |
| 11:43 ET | 5200 | 1.205 |
| 11:45 ET | 100 | 1.21 |
| 11:48 ET | 2790 | 1.205 |
| 11:50 ET | 1700 | 1.2 |
| 11:54 ET | 12421 | 1.205 |
| 11:56 ET | 10400 | 1.205 |
| 11:57 ET | 700 | 1.205 |
| 11:59 ET | 500 | 1.205 |
| 12:01 ET | 700 | 1.205 |
| 12:03 ET | 2076 | 1.2097 |
| 12:06 ET | 2900 | 1.2 |
| 12:08 ET | 1500 | 1.2 |
| 12:10 ET | 6376 | 1.2 |
| 12:12 ET | 800 | 1.195 |
| 12:14 ET | 100 | 1.195 |
| 12:15 ET | 7362 | 1.19 |
| 12:19 ET | 400 | 1.185 |
| 12:21 ET | 1500 | 1.185 |
| 12:24 ET | 490 | 1.185 |
| 12:26 ET | 4500 | 1.1889 |
| 12:28 ET | 4138 | 1.1889 |
| 12:30 ET | 6101 | 1.18 |
| 12:32 ET | 3200 | 1.19 |
| 12:33 ET | 7642 | 1.195 |
| 12:35 ET | 20600 | 1.1988 |
| 12:37 ET | 900 | 1.195 |
| 12:39 ET | 600 | 1.195 |
| 12:42 ET | 960 | 1.195 |
| 12:44 ET | 1581 | 1.2 |
| 12:46 ET | 15661 | 1.205 |
| 12:48 ET | 1800 | 1.21 |
| 12:50 ET | 2405 | 1.2011 |
| 12:51 ET | 20350 | 1.205 |
| 12:53 ET | 1702 | 1.21 |
| 12:55 ET | 16558 | 1.195 |
| 12:57 ET | 13289 | 1.195 |
| 01:00 ET | 120669 | 1.19 |
Nov 13, 2024
DJ Heron Therapeutics Is Maintained at Buy by Needham, from 4:52AM ET on Wednesday Nov 13, 2024 by Dow Jones
4:52AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance, from 7:55AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:55AM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Heron Therapeutics 3Q Loss/Shr 3c >HRTX, from 7:55AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:55AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 4, 2024
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors, from 5:00PM ET on Monday Nov 04, 2024 by Dow Jones
5:00PM ET on Monday Nov 04, 2024 by Dow JonesPress Release: Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors, from 5:00PM ET on Monday Nov 04, 2024 by Dow Jones
5:00PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Heron Therapeutics Inc | 176.4M | -6.5x | --- |
Seres Therapeutics Inc | 149.7M | -0.9x | --- |
2Seventy Bio Inc | 190.4M | -2.2x | --- |
Karyopharm Therapeutics Inc | 109.8M | -1.1x | --- |
Sutro Biopharma Inc | 221.8M | -1.6x | --- |
CytomX Therapeutics Inc | 79.8M | 6.3x | --- |
Company Information
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Contact Information
- Headquarters
- 4242 Campus Point Court, Suite 200SAN DIEGO, CA, United States 92121
- Phone
- 858-251-4400
- Fax
- ---
Executives
- Chairman of the Board
- Adam Morgan
- Chief Executive Officer, Director
- Craig Collard
- Chief Financial Officer, Principal Accounting Officer
- Ira Duarte
- Executive Vice President, Chief Development Officer
- William Forbes
- Vice President
- Lisa Peraza
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $176.4M |
|---|---|
Revenue (TTM) | $137.7M |
Shares Outstanding | 152.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.69 |
EPS | $-0.18 |
Book Value | $-0.23 |
P/E Ratio | -6.5x |
Price/Sales (TTM) | 1.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -18.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
